Allen Capital Group LLC Buys Shares of 437 Eli Lilly and Company (NYSE:LLY)

Allen Capital Group LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 437 shares of the company’s stock, valued at approximately $255,000.

Several other hedge funds have also made changes to their positions in the stock. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter worth $26,000. Wealth Alliance increased its holdings in shares of Eli Lilly and Company by 4.1% in the 4th quarter. Wealth Alliance now owns 7,221 shares of the company’s stock worth $4,209,000 after acquiring an additional 285 shares during the period. Signet Financial Management LLC lifted its position in Eli Lilly and Company by 0.5% in the 4th quarter. Signet Financial Management LLC now owns 10,467 shares of the company’s stock valued at $6,101,000 after purchasing an additional 52 shares during the last quarter. Main Street Research LLC boosted its stake in Eli Lilly and Company by 3.4% during the 4th quarter. Main Street Research LLC now owns 3,132 shares of the company’s stock valued at $1,826,000 after purchasing an additional 103 shares during the period. Finally, Octavia Wealth Advisors LLC grew its position in Eli Lilly and Company by 43.6% in the 4th quarter. Octavia Wealth Advisors LLC now owns 734 shares of the company’s stock worth $428,000 after purchasing an additional 223 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on LLY shares. Barclays boosted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a report on Monday. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Morgan Stanley upped their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $746.56 on Wednesday. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78. The business’s 50-day moving average price is $763.51 and its two-hundred day moving average price is $657.01. The company has a market capitalization of $709.35 billion, a P/E ratio of 128.72, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the company earned $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.